The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease
| Image |  |
|---|---|
| Description | scientific article published on 25 April 2011 |
| Author/s |
author: Peter Gmeiner |
| Publication date | April 25, 2011 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |